← All countries · Eastern Mediterranean
99%
MCV1
2025 · WHO/UNICEF estimate
98%
DTP3
2025 · WHO/UNICEF estimate
98%
IPV complete
2025 · WHO/UNICEF estimate
98%
HepB3
2025 · WHO/UNICEF estimate
1,072
Measles cases
2025 reported
490
Pertussis (whooping cough) cases
2025 reported
Two kinds of number live on this page. Coverage is the share of the target cohort vaccinated, as estimated by WHO and UNICEF each July from the country's reports, surveys and other evidence, shown beside what the country itself reported. Reported cases are what the national surveillance system sent to WHO; they are a floor, not a count of infections. Every row carries a grade; hover or focus it for the reason, or read how grades are assigned.
Vaccination coverage
| Vaccine | Latest estimate | Country-reported | Trend since 2000 | Data quality |
|---|---|---|---|---|
| BCGTuberculosis vaccine at birth | 96%2025 · WHO/UNICEF estimate | 95.8% | A · strong | |
| DTP1First dose of diphtheria-tetanus-pertussis | 99%2025 · WHO/UNICEF estimate | 98.6% | A · strong | |
| DTP3Third dose of diphtheria-tetanus-pertussis (the WHO benchmark of a working programme) | 98%2025 · WHO/UNICEF estimate | 97.6% | B · good | |
| IPV1First dose of inactivated polio vaccine | 98%2025 · WHO/UNICEF estimate | 97.5% | B · good | |
| IPV completeInactivated polio vaccine, complete primary series | 98%2025 · WHO/UNICEF estimate | 97.5% | C · weak | |
| MCV1First dose of measles-containing vaccine | 99%2025 · WHO/UNICEF estimate | 103.8% | B · good | |
| MCV2Second dose of measles-containing vaccine | 98%2025 · WHO/UNICEF estimate | 98.5% | B · good | |
| RCV1First dose of rubella-containing vaccine | 99%2025 · WHO/UNICEF estimate | 103.8% | B · good | |
| HepB3Third dose of hepatitis B vaccine | 98%2025 · WHO/UNICEF estimate | 97.6% | A · strong | |
| HepB birthHepatitis B birth dose within 24 hours | 91%2025 · WHO/UNICEF estimate | 90.6% | A · strong | |
| Hib3Third dose of Haemophilus influenzae type b vaccine | 98%2025 · WHO/UNICEF estimate | 97.6% | A · strong | |
| PCV1Pneumococcal conjugate vaccine, first dose | 93.7%2025 · Administrative (country-reported) | 93.7% | D · poor | |
| PCV completePneumococcal conjugate vaccine, final dose of the schedule | 54%2025 · WHO/UNICEF estimate | 54.4% | C · weak | |
| RotaCRotavirus vaccine, complete series | 57%2025 · WHO/UNICEF estimate | 57.5% | C · weak | |
| Yellow feverYellow fever vaccine (countries at risk) | 0%2017 · Administrative (country-reported) | 0% | too few points | D · poor |
| MenAMeningococcal A conjugate (meningitis belt) | 0%2017 · Administrative (country-reported) | 0% | too few points | D · poor |
| JEJapanese encephalitis vaccine (countries at risk) | 0%2017 · Administrative (country-reported) | 0% | too few points | D · poor |
| TCVTyphoid conjugate vaccine | —% · Administrative (country-reported) | — | too few points | no data |
| PABProtection at birth against neonatal tetanus (maternal tetanus doses) | 97%2024 · WHO/UNICEF estimate | — | D · poor |
Reported vaccine-preventable disease
| Disease | Reported cases | Incidence rate | Trend since 2000 | Data quality |
|---|---|---|---|---|
| Measles all countries · vaccine evidence | 1,0722025 | 11.6per 1,000,000 total population | A · strong | |
| Rubella all countries · vaccine evidence | 142025 | 0.2per 1,000,000 total population | A · strong | |
| Congenital rubella syndrome all countries · vaccine evidence | 02025 | 0per 10,000 live births | A · strong | |
| Mumps all countries · vaccine evidence | 10,4172000 | 156.8per 1,000,000 total population | too few points | no data |
| Pertussis (whooping cough) all countries · vaccine evidence | 4902025 | 5.3per 1,000,000 total population | A · strong | |
| Diphtheria all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | A · strong | |
| Tetanus (total) all countries · vaccine evidence | 72025 | 0.1per 1,000,000 total population | A · strong | |
| Neonatal tetanus all countries · vaccine evidence | 02025 | 0per 1,000 live births | A · strong | |
| Polio (paralytic) all countries · vaccine evidence | 02021 | 0per 1,000,000 <15 population | D · poor | |
| Yellow fever all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | C · weak | |
| Japanese encephalitis all countries · vaccine evidence | 02024 | 0per 1,000,000 total population | D · poor | |
| Invasive meningococcal disease all countries · vaccine evidence | 332025 | 0.4per 1,000,000 total population | C · weak | |
| Typhoid all countries · vaccine evidence | 672025 | 0.7per 1,000,000 total population | B · good |
National schedule (latest WHO listing)
Show the schedule (54 rows)
| Vaccine | Dose | Age | Target group | Comment |
|---|---|---|---|---|
| BCGBCG (Baccille Calmette Guérin) vaccine | 1 | B | General/routine | |
| DTDT (Tetanus toxoid and diphtheria, children's dose) vaccine | 1 | M2 | Risk group(s) | children with contraindication of pertussis vaccine |
| DTDT (Tetanus toxoid and diphtheria, children's dose) vaccine | 2 | M4 | Risk group(s) | children with contraindication of pertussis vaccine |
| DTDT (Tetanus toxoid and diphtheria, children's dose) vaccine | 3 | M6 | Risk group(s) | children with contraindication of pertussis vaccine |
| DTDT (Tetanus toxoid and diphtheria, children's dose) vaccine | 5 | M18 | Risk group(s) | children with contraindication of pertussis vaccine |
| DTDT (Tetanus toxoid and diphtheria, children's dose) vaccine | 6 | Y6 | Risk group(s) | children with contraindication of pertussis vaccine |
| DTWPDTwP (Whole cell) vaccine | 4 | M18 | General/routine | |
| DTWPDTwP (Whole cell) vaccine | 5 | Y6 | General/routine | |
| DTWPHIBHEPBDTwP-Hib-HepB (Whole cell) vaccine | 1 | M2 | General/routine | |
| DTWPHIBHEPBDTwP-Hib-HepB (Whole cell) vaccine | 2 | M4 | General/routine | |
| DTWPHIBHEPBDTwP-Hib-HepB (Whole cell) vaccine | 3 | M6 | General/routine | |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 1 | B | General/routine | |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 2 | M2 | Risk group(s) | doses at 2 and 6 months for children with contraindication of pertussis vaccine, and high risk groups if not vaccinated before |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 3 | M6 | Risk group(s) | doses at 2 and 6 months for children with contraindication of pertussis vaccine, and high risk groups if not vaccinated before |
| HIBHib (Haemophilus influenzae type B) vaccine | 1 | M2 | Risk group(s) | children with contraindication of pertussis vaccine |
| HIBHib (Haemophilus influenzae type B) vaccine | 2 | M4 | Risk group(s) | children with contraindication of pertussis vaccine |
| HIBHib (Haemophilus influenzae type B) vaccine | 3 | M6 | Risk group(s) | children with contraindication of pertussis vaccine |
| HPV2HPV-2 (Human papillomavirus 2-valent) vaccine | 1 | <Y25 | Risk group(s) | No specific target group, however this vaccine distributed in private sector. HPV vaccine is not under EPI program |
| HPV2HPV-2 (Human papillomavirus 2-valent) vaccine | 2 | <Y25 | Risk group(s) | No specific target group, however this vaccine distributed in private sector. HPV vaccine is not under EPI program |
| HPV4HPV-4 (Human papillomavirus 4-valent) vaccine | 1 | <Y25 | Risk group(s) | No specific target group however this vaccine distributed by private sector. HPV vaccine is not under EPI program |
| HPV4HPV-4 (Human papillomavirus 4-valent) vaccine | 2 | <Y25 | Risk group(s) | No specific target group however this vaccine distributed by private sector. HPV vaccine is not under EPI program |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | >Y65 | Adults | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Health workers | Health and care workers | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Pregnant women | Pregnant women | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Risk group(s) | Adults with chronic conditions, residents living in long-term care facilities | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | M1-M59 | General/routine | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | Risk group(s) | Children with chronic conditions | |
| IPVIPV (Inactivated polio vaccine) | 1 | M4 | General/routine | |
| IPVIPV (Inactivated polio vaccine) | 2 | M6 | General/routine | |
| MEASLESMeasles vaccine | 1 | M6 | General/routine · SUBNATIONAL | As zero dose in 3 South-Eastern provinces (all children in the 3 provinces are administered the vaccine at 6 months.) |
| MEN_ACYW_135CONJMeningococcal ACYW conjugate vaccine | 1 | Risk group(s) | outbreak response in dormitories or prisons, military and for Haj pilgrims, Umra travelers | |
| MMRMMR (Measles, mumps and rubella) vaccine | 1 | M12 | General/routine | |
| MMRMMR (Measles, mumps and rubella) vaccine | 2 | M18 | General/routine | |
| MRMR (Measles and rubella) vaccine | 1 | Risk group(s) | outbreak response | |
| OPVOPV (Oral polio vaccine) | 1 | B | General/routine | |
| OPVOPV (Oral polio vaccine) | 2 | M2 | General/routine | |
| OPVOPV (Oral polio vaccine) | 3 | M4 | General/routine | |
| OPVOPV (Oral polio vaccine) | 4 | M6 | General/routine | |
| OPVOPV (Oral polio vaccine) | 5 | M18 | General/routine | |
| OPVOPV (Oral polio vaccine) | 6 | Y6 | General/routine | |
| PCV10PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine | 1 | M2 | General/routine | |
| PCV10PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine | 2 | M4 | General/routine | |
| PCV10PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine | 3 | M12 | General/routine | |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 1 | Risk group(s) | high risk groups, this vaccine is distributed by private sector | |
| PPV23PPV-23 (Pneumococcal polysaccharide 23-valent) vaccine | 1 | Risk group(s) | High risk groups for pneumococcal infections, this vaccine distributed by private sector | |
| RABIESRabies vaccine | 1 | Risk group(s) | animal bite cases and high-risk groups | |
| ROTAVIRUS_5RV-5 (Rotavirus 5-valent) vaccine | 1 | M2 | General/routine | |
| ROTAVIRUS_5RV-5 (Rotavirus 5-valent) vaccine | 2 | M4 | General/routine | |
| ROTAVIRUS_5RV-5 (Rotavirus 5-valent) vaccine | 3 | M6 | General/routine | |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 1 | Y25 | Adults | The booster dose of Td vaccine is recommended at 15 Y/O and repeated every 10 years later |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 2 | +Y10 | Adults | The booster dose of Td vaccine is recommended at 15 Y/O and repeated every 10 years later |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 6 | Y15 | General/routine | Recommended at 15 Y/O and repeated every 10 years later |
| VARICELLAVaricella vaccine | 1 | Risk group(s) | children with lymphatic and hematologic malignancies and their siblings, multiple sclerosis patients who have negative serology test for varicella | |
| YFYF (Yellow fever) vaccine | 1 | Travellers | travellers to endemic countries |
Compare schedules across 31 countries on the schedule hub.
Data and sources
- Download this country's data (JSON): every year, every antigen and disease, with the grade reasons.
- Coverage: WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) and country-reported administrative/official coverage, from the WHO Immunization Data Portal export downloaded 21 October 2026.
- Reported cases and incidence: WHO/UNICEF Joint Reporting Form, same export. Incidence denominators are stated per row.
- Schedule: WHO vaccine-schedule export, latest listing year.